CompletedNCT04108104
Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Addiction While Avoiding Major Side Effects
Medication studyAges 18–65France
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Abbeville and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 30, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 154
- Sponsor
- Kinnov Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04108104
- Official title
Show the full official title
Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder
Get this study by email
Recruitment & locations
CompletedAbbeville · Agen · Astillé
27 more locations
- Bayonne
- Bersée
- Brest
- Bron
- Clermont-Ferrand
- Créteil
- Dijon
- Épagny
- La Couronne
- La Rochelle
- Le Puy-en-Velay
- Limoges
- Lyon
- Marseille
- Montpellier
- Nancy
- Nantes
- Nice
- Nîmes
- Orléans
- Paris
- Pau
- Rennes
- Saint-Martin-d'Hères
- Saint-Nazaire
- Saint-Rémy
- Tours
Questions about this study
Who is behind this study?
The study sponsor is Kinnov Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Cyproheptadine and Alpress LP.
Who was this study for?
Listed age limits: 18 years to 65 years.
